Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof
The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors and polyvalent vaccines comprising the recombinant HVT vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.
1. A composition or vaccine comprising a recombinant herpesvirus of turkeys (HVT) vector comprising a first heterologous polynucleotide coding for and expressing an Infectious Laryngotracheitis Virus (ILTV) glycoprotein D (gD) antigen, wherein the ILTV gD antigen has at least 80% sequence identity to SEQ ID NO:17, the first heterologous polynucleotide has at least 70% sequence identity to SEQ ID NO:16, or both.
2. The composition or vaccine of claim 1 , wherein the HVT vector further comprises a second heterologous polynucleotide coding for and expressing an Infectious Bursal Disease Virus (IBDV) VP2 antigen, an Infectious Laryngotracheitis Virus (ILTV) glycoprotein D (gD) antigen, or a Newcastle Disease Virus F (NDV-F) antigen.
3. The composition or vaccine of claim 2 , wherein the second heterologous polynucleotide codes for and expresses the IBDV VP2 antigen, and wherein the IBDV VP2 antigen has at least 80% sequence identity to SEQ ID NO:2.
4. The composition or vaccine of claim 1 , wherein the ILTV gD antigen has at least 95% sequence identity to SEQ ID NO:17.
5. The composition or vaccine of claim 2 , wherein the second heterologous polynucleotide codes for and expresses the NDV-F antigen, and wherein the NDV-F antigen has at least 80% sequence identity to SEQ ID NO:5 or 22.
6. The composition or vaccine of claim 2 , wherein the second heterologous polynucleotide codes for and expresses the IBDV VP2 antigen, and wherein the second heterologous polynucleotide has at least 70% sequence identity to SEQ ID NO:1.
7. The composition or vaccine of claim 1 , wherein the first heterologous polynucleotide has at least 95% sequence identity to SEQ ID NO:16.
8. The composition or vaccine of claim 2 , wherein the second heterologous polynucleotide codes for and expresses the NDV-F antigen, and wherein the second heterologous polynucleotide has at least 70% sequence identity to SEQ ID NO:3, 4, or 21.
9. The composition or vaccine of claim 1 , wherein the first heterologous polynucleotide is operably linked to an mCMV IE promoter, an SV40 promoter, an HHV3gB promoter, or a reverse HHV3gB promoter.
10. The composition or vaccine of claim 2 , wherein the first and second heterologous polynucleotides are linked by IRES or P2A.
11. The composition or vaccine of claim 1 , wherein the first heterologous polynucleotide is inserted in the IG1 locus and/or SORF-US2 locus of the HVT genome.
12. The composition or vaccine of claim 1 , wherein the first heterologous polynucleotide is operably linked to an mCMV IE or an SV40 promoter at the 5′ end, and IRES or P2A at the 3′ end.
13. The composition or vaccine of claim 1 , further comprising a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle, and/or adjuvant.
14. A recombinant HVT vector comprising:
a first heterologous polynucleotide coding for and expressing an Infectious Laryngotracheitis Virus (ILTV) glycoprotein D (gD) antigen, wherein the ILTV gD antigen coded by the first heterologous polynucleotide has at least 80% sequence identity to SEQ ID NO:17, the first heterologous polynucleotide has at least 70% sequence identity to SEQ ID NO: 16, or both; and a second heterologous polynucleotide coding for and expressing an Infectious Burial Disease Virus (IBDV) VP2 antigen, an Infectious Laryngotracheitis Virus (ILTV) glycoprotein D (gD) antigen, or a Newcastle Disease Virus F (NDV-F) antigen.
15. The recombinant HVT vector of claim 14 , wherein the second heterologous polynucleotide codes for and expresses the IBDV VP2 antigen, and wherein the IBDV VP2 antigen has at least 80% sequence identity to SEQ ID NO:2.
16. The recombinant HVT vector of claim 14 , wherein the ILTV gD antigen coded by the first heterologous polynucleotide has at least 95% sequence identity to SEQ ID NO:17.
17. The recombinant HVT vector of claim 14 , wherein the second heterologous polynucleotide codes for and expresses the NDV-F antigen, and wherein the NDV-F antigen has at least 80% sequence identity to SEQ ID NO:5 or 22.
18. The recombinant HVT vector of claim 14 , wherein the second heterologous polynucleotide codes for and expresses the IBDV VP2 antigen, and wherein the second heterologous polynucleotide has at least 70% sequence identity to SEQ ID NO: 1.
19. The recombinant HVT vector of claim 14 , wherein the first heterologous polynucleotide has at least 95% sequence identity to SEQ ID NO:16.
20. The recombinant HVT vector of claim 14 , wherein the second heterologous polynucleotide codes for and expresses the NDV-F antigen, and wherein the second heterologous polynucleotide has at least 70% sequence identity to SEQ ID NO:3, 4, or 21.
21. The recombinant HVT vector of claim 14 , wherein the first and second heterologous polynucleotides are each operably linked to an mCMV IE promoter, an SV40 promoter, an HHV3gB promoter, or a reverse HHV3gB promoter.
22. The recombinant HVT vector of claim 14 , wherein the first and second heterologous polynucleotides are linked by IRES or P2A.
23. The recombinant HVT vector of claim 14 , wherein the first and second heterologous polynucleotides are inserted in the IG1 locus and/or SORF-US2 locus of the HVT genome.
24. The recombinant HVT vector of claim 14 , wherein the first heterologous polynucleotide is operably linked to an mCMV IE or an SV40 promoter at the 5′ end, and IRES or P2A at the 3′ end.